US/UK/Canada

Share

Contacts

  • Bronwyn Brophy O'Connor

    CEO


    Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden
    http://www.vitrolifegroup.com
  • Patrik Tolf

    CFO


    Vitrolife AB (publ), Box 9080, 400 92 Göteborg, Sweden
    +46 31 766 90 21
    http://www.vitrolifegroup.com
  • Vitrolife AB
    +46 (0)31 721 80 00
    +46 (0)31 721 80 99
    http://www.vitrolifegroup.com

    • Links

    Pick a time period -
    Tags ( Active)

    Interim report January-June 2016: Good growth and broadened product portfolio

    Second quarter: · Sales amounted to SEK 208 (184) million, corresponding to an increase of 13 percent in SEK. Net sales growth was 15 percent in local currency. · Operating income before depreciation and amortisation (EBITDA) amounted to SEK 74 (62) million, corresponding to a margin of 35 (34) percent. · Net income amounted to SEK 48 (39) million, which gave earnings per share of SEK 2.21 (1.77). · Acquisition of all the shares in OCTAX and MTG, world-leaders in the field of laser technology for IVF. · Vitrolife introduces EmbryoScope+ and broadens the time-lapse product

    Interim report January-June 2015: Good growth and strengthened income

    Second quarter: · Sales amounted to SEK 184 (129) million, corresponding to an increase of 42 percent in SEK. Sales growth was 27 percent in local currency. The acquisition of Vitrolife A/S (formerly Unisense FertiliTech A/S) contributed SEK 32 million to sales. Adjusted for this, sales growth amounted to 5 percent in local currency. · Operating income before depreciation and amortization (EBITDA) amounted to SEK 62 (38) million, corresponding to a margin of 34 (29) percent. Fluctuations in exchange rates had a positive effect of SEK 9 million on EBITDA. · Net income amounted to

    Vitrolife och Biolamina increase collaboration within stem cells

    Vitrolife AB (publ) has collaborated with the Stockholm-based Biolamina AB within the stem-cell field since 2012. The companies have now decided to increase their collaboration and, as part of this greater collaboration, Vitrolife has invested in Biolamina together with the company’s present owners.Vitrolife AB (publ) has collaborated with the Stockholm-based Biolamina AB within the stem-cell field since 2012. During spring the collaboration resulted in the launch of a new freeze medium for stem cells, FREEZEstem™, which has been developed and produced by Vitrolife and is now marketed

    Interim report January – September 2013

    High growth and improved incomeThird quarter: Continuing operations · Sales growth was 33 percent in local currency. Sales amounted to SEK 109 (83) million, corresponding to an increase of 31 percent in SEK. · Operating income (EBIT) amounted to SEK 23 (15) million, corresponding to an operating margin of 21 (18) percent. · The comparative figures for 2012 relate to continuing operations, fertility, unless otherwise stated. · Net income amounted to SEK 17 (9) million, which gave earnings per share of SEK 0.85 (0.45). · Agreement with Xvivo Perfusion AB to terminate

    Conference call interim report

    Invitation to attend Vitrolife’s conference call regarding presentation of the interim report for the period January - September 2013. The presentation will be held in English.Time: Thursday, November 7, 2013 at 10 a.m. CET. Registration can preferably be done in advance under the following link: https://eventreg2.conferencing.com/webportal3/reg.html?Acc=432388&Conf=213994 or shortly before the conference starts on: · Sweden dial in number: +46 (0)8 5052 0114 · UK dial in number: +44 (0)207 1620 177 Conference name: Vitrolife, conference ID: 937804 Vitrolife

    Interim report January – June 2013

    Continuing good performanceSecond quarter: Continuing operations · Sales growth was 29 percent in local currency. Sales amounted to SEK 116 (95) million, corresponding to an increase of 22 percent in SEK. · Operating income (EBIT) amounted to SEK 19 (13) million, corresponding to an operating margin of 16 (13) percent. · The comparative figures for 2012 relate to continuing operations, fertility, unless otherwise stated. · Net income amounted to SEK 12 (11) million, which gave earnings per share of SEK 0.62 (0.54). · Dividend of SEK 0.60 (0.60) per share, in total SEK 11,

    Interim report January-March 2013: High growth and increased income

    First quarter Continuing operations: · Sales growth was 27 percent in local currency. Sales amounted to SEK 105 (86) million, corresponding to an increase of 22 percent in SEK. · Operating income (EBIT) amounted to SEK 17 (10) million, corresponding to an operating margin of 16 (12) percent. · Net income amounted to SEK 12 (7) million, which gave earnings per share of SEK 0.61 (0.38). After the end of the period · During 2010 Vitrolife entered into a collaboration agreement with the Danish company HertArt ApS with a view to developing a new range of disposable plastic

    Conference call interim report

    Invitation to attend Vitrolife’s conference call regarding presentation of the interim report for the period January - March 2013. The presentation will be held in English.Time: Friday, April 19, 2013 at 10 a.m. CET. Registration can preferably be done in advance under the following link: https://eventreg1.conferencing.com/webportal3/reg.html?Acc=800440&Conf=187229 or shortly before the conference starts on: Sweden dial in number: +46 (0)8 5052 0110 UK dial in number: +44 (0)20 7162 0077 Conference name: Vitrolife, conference ID: 931066 Vitrolife participants:Thomas

    Notice of Annual General Meeting of Vitrolife AB (publ)

    The Annual General Meeting of Vitrolife AB (publ) will take place on Monday April 29, 2013, at 5 p.m. in the company’s premises at Gustaf Werners gata 2 in Gothenburg. Notice of attendance at the Annual General Meeting shall be given no later than Tuesday, April 23, 2013, at 12 noon.Shareholders wishing to participate at the Annual General Meeting shall notify the company by mail to Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden, Att: Anita Ahlqvist, by phone +46 31 721 80 83, by fax +46 31 721 80 99 or by e-mail aahlqvist@vitrolife.com. Name/business name, personal

    Report on operations 2012

    High growth and improved operating marginFourth quarter Continuing operations: · Sales growth was 24 percent in local currency. Sales amounted to SEK 98 (82) million, corresponding to an increase of 20 percent in SEK. · Operating income (EBIT) amounted to SEK 12 (2) million, corresponding to an operating margin of 12 (2) percent. · On October 1 the transplantation business was distributed to the shareholders of Vitrolife, and it is thus reported in this interim report as discontinued operations. The distribution entailed a non-taxable financial capital gain of SEK 303 million

    Vitrolife’s share capital and number of shares on November 30, 2012

    As per November 30, 2012, the total number of shares in Vitrolife AB (publ) amounts to 19,830,936, of which Vitrolife itself holds 0 shares. The share capital amounts to SEK 20,227,554.74.At the beginning of the month the total number of shares in the company amounted to 19,562,769, of which Vitrolife itself held 0 shares. The share capital amounted to SEK 19,954,024.38 The increase in the number of shares by 268.167 during the month of November is due to the private placement that was directed to the previous owners of Cryo Management Ltd to partly finance the acquisition of Cryo

    Interim report January – September 2012

    Continued strong growth and resolution to distribute TransplantationThird quarterGroup, including discontinuing operations · Sales growth was 17 percent in local currency. Sales amounted to SEK 97 (85) million, corresponding to an increase of 14 percent in SEK. · Sales growth within Fertility was 16 percent in local currency and 13 percent in SEK. Sales growth within Transplantation was 23 percent in local currency and 22 percent in SEK. · Operating income (EBIT) amounted to SEK 13 (14) million. One-time expenses of SEK 5 million were charged against operating income ahead of

    Private placement regarding Cryo Management fully subscribed

    The Extraordinary General Meeting of Vitrolife held on September 24 adopted a resolution regarding a private placement of EUR 1.352.315 in order to partly finance the acquisition of Cryo Management Ltd. In accordance with the resolution, the board of directors of Vitrolife has resolved to determine that the company’s share capital shall be increased with not more than SEK 273.530,34 by an issue of not more than 268,167 shares. The new share issue was fully subscribed.The Extraordinary General Meeting of Vitrolife held September 24 adopted a resolution regarding a private placement of EUR 1.

    Election committee for Vitrolife AB (publ)

    The following people have been appointed as members of Vitrolife’s election committee for the Annual General Meeting in 2013:Henrik Blomquist, representing Bure Equity ABJohan Ståhl, representing Lannebo FonderMartin Lewin, representing Eccenovo AB and Thomas OlaussonPatrik Tigerschiöld, Chairman of the Board The appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at the Annual General Meeting of Vitrolife on April 19, 2012. The Annual General Meeting of Vitrolife AB (

    Vitrolife completes acquisition of Cryo Management Ltd

    On June 29 Vitrolife announced that the company had entered into an agreement to acquire 100% ownership in Cryo Management Ltd. Vitrolife has now completed the transaction and Cryo Management Ltd is now a part of Vitrolife.Cryo Management Ltd is one of the world’s leading players within time-lapse for IVF, developer of Primo Vision time-lapse embryo monitoring system. The company has approximately 20 employees and is based in Hungary. The acquisition was completed under essentially the same conditions as were communicated on June 29. “We are pleased to be able to welcome our new

    New financial objectives for Vitrolife

    After the adoption of a resolution to spin off Vitrolife’s transplantation business, Vitrolife’s Board has set new financial objectives for the company.Vitrolife’s new financial objectives are as follows: Vitrolife’s Board considers that Vitrolife should have a strong capital base in order to enable continued high growth, both organically and through acquisitions. The company’s net debt in relation to EBITDA should normally not exceed 3 times. Vitrolife’s Board targets a profitable growth. The objective for Vitrolife’s growth over a three year period is an increase in sales by an average

    Collaboration agreement within IUI, Intra-Uterine Insemination

    Vitrolife is entering into a collaboration agreement with ParentPlus LLC, with the aim of developing new products for IUI (Intra-Uterine Insemination, artificial insemination).In many countries IUI treatment is a requirement before IVF (In Vitro Fertilization) treatment can begin. It is estimated that there is a market for between 4-6 million treatments a year, with a market value of SEK 1-2 billion. IUI, “artificial insemination”, is a process where the sperm are prepared by separating them from the seminal fluid and then injecting them so that a high concentration of active and mobile

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe